表紙
市場調查報告書
商品編碼
838360

鐮狀細胞貧血 (SCD) 治療的全球市場:產業分析、市場規模、市場佔有率、成長率、市場趨勢、預測

Global Sickle Cell Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2018 to 2025

出版日期: | 出版商: Value Market Research | 英文 | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球鐮狀細胞貧血 (SCD) 治療市場調查,市場定義和概要,價值鏈,市場成長的各種影響因素及市場機會分析,各治療方法、地區的趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等資訊彙整。

第1章 簡介

第2章 摘要整理

第3章 市場分析

  • 簡介
  • 價值鏈分析
  • 成長推動因素
  • 阻礙成長要素
  • 市場機會
  • 波特的五力分析

第4章 鐮狀細胞貧血 (SCD) 治療市場分析:各類型

  • 疫苗、抗體的預防感染市場
  • 輸血市場
  • 羥基脲治療藥市場
  • 骨髓細胞的移植

第5章 鐮狀細胞貧血 (SCD) 治療市場分析:各用途

  • 醫院
  • ASC (外科門診診療所)
  • 診療所
  • 其他

第6章 鐮狀細胞貧血 (SCD) 治療市場分析:各地區

  • 北美
  • 歐洲 (EU)
  • 亞太地區
  • 南美
  • 中東、非洲 (MEA)

第7章 競爭環境

  • 市場競爭
  • 聯盟、合作、協定
  • M&A
  • 新產品的開發
  • 其他

第8章 企業簡介

  • Acceleron Pharma
  • Alnylam Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Baxter
  • Bluebird Bio
  • Bristol-Myers Squibb
  • Eli Lilly
  • Emmaus Life Sciences
  • Global Blood Therapeutics Novartis
  • Pfizer
  • Sangamo Therapeutics
  • Tentative TOC
目錄

The report on Global Sickle Cell Disease Treatment Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2025. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

  • Drivers
    • Growing patient pool and high unmet medical needs
    • Increasing investment by the government in order to improve the healthcare services
  • Restraints
    • High cost of treatment and unavailability of required drugs

Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. This market is classified into different segments with detailed analysis of each with respect to geography for the study period:

  • Base Year: 2018
  • Estimated Year: 2019
  • Forecast Till: 2025

The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.

The report classifies the market into different segments based on type and application. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

The report also covers the complete competitive landscape of the worldwide market with company profiles of key players such as Acceleron Pharma, Alnylam Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Baxter, Bluebird Bio, Bristol-Myers Squibb, Eli Lilly, Emmaus Life Sciences, Global Blood Therapeutics Novartis, Pfizer, Sangamo Therapeutics. A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.

SEGMENTATIONS IN THE REPORT:

By Type:

  • Infection Prevention with Vaccination and Antibiotics
  • Blood Transfusion
  • The Medication Hydroxycarbamide
  • A Transplant of Bone Marrow Cells

By Applications:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Others

By Geography:

  • North America (NA) - US, Canada & Rest of North America
  • Europe (EU) - UK, Germany, France & Rest of Europe
  • Asia Pacific (APAC) - China, Japan, India & Rest of APAC
  • Latin America (LA) - Brazil & Rest of Latin America
  • Middle East & Africa (MEA) - Middle East and Africa

Table of Contents

1. INTRODUCTION

  • Report Description
  • Research Scope
  • Research Methodology

2. EXECUTIVE SUMMARY

  • Market Highlight
  • Global Sickle cell disease treatment Market: Snapshot

3. MARKET ANALYSIS

  • Introduction
  • Value Chain Analysis
  • Drivers
  • Restraints
  • Opportunities
  • Porter's Five Forces Analysis

4. SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS BY TYPES

  • Market In Infection Prevention with Vaccination and Antibiotics
  • Market In Blood Transfusion
  • Market In The Medication Hydroxycarbamide
  • Market In A Transplant of Bone Marrow Cells

5. SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS BY APPLICATION

  • Market In Hospitals
  • Market In Ambulatory Surgical Centers
  • Market In Clinics
  • Market In Others

6. SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • North America (NA)
  • North America Market Estimates
  • North America Market Estimates By Country
  • United States (U.S.)
  • Canada
  • Rest Of North America
  • Europe (EU)
  • Europe Market Estimates
  • Europe Market Estimates By Country
  • United Kingdom (UK)
  • Germany
  • France
  • Rest Of Europe
  • Asia Pacific (APAC)
  • Asia Pacific Market Estimates
  • Asia Pacific Market Estimates By Country
  • China
  • Japan
  • India
  • Rest Of Asia Pacific
  • Latin America (LA)
  • Latin America Market Estimates
  • Latin America Market Estimates By Country
  • Brazil
  • Rest Of Latin America
  • Middle East And Africa (MEA)
  • Middle East And Africa Market Estimates
  • Middle East And Africa Market Estimates By Country
  • Middle East
  • Africa

7. COMPETITIVE LANDSCAPE OF THE SICKLE CELL DISEASE TREATMENT COMPANIES

  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments

8. COMPANY PROFILES OF THE SICKLE CELL DISEASE TREATMENT INDUSTRY (Company Overview, Financial, Major Products & Recent Development)

  • Acceleron Pharma
  • Alnylam Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Baxter
  • Bluebird Bio
  • Bristol-Myers Squibb
  • Eli Lilly
  • Emmaus Life Sciences
  • Global Blood Therapeutics Novartis
  • Pfizer
  • Sangamo Therapeutics
  • Tentative TOC